DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC
Advanced Science · 2026
DOI: 10.1002/advs.76266 ↗At a glance
Journal article in Advanced Science, 2026. Written by Shijie Qian and 10 co-authors. Institution: Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Major MEDLINE topics: Sunitinib, Carcinoma, Renal Cell, Drug Resistance, Neoplasm, Vascular Endothelial Growth Factor A. Cited 1 times so far (Crossref); 63 references. The full text is freely available (open access, CC BY 4.0). Funded by: Jiangsu Provincial Medical Key Discipline (Laboratory), Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University, National Natural Science Foundation of China.
Abstract (original language)
Sunitinib, a tyrosine kinase inhibitor, exerts its crucial therapeutic effect in renal cell carcinoma (RCC) primarily by inhibiting tumor angiogenesis and cellular proliferation. However, despite its initial efficacy, therapeutic resistance invariably develops in many RCC patients, underscoring the urgent need for novel strategies to overcome this limitation. We constructed patient‐derived xenograft (PDX) models using surgically resected RCC tissues and subsequently established stable sunitinib‐resistant and sunitinib‐sensitive PDX models. Proteomic profiling was performed to identify key regulators involved in sunitinib resistance. Mechanistic studies were conducted to investigate the molecular interactions among DHODH, TRIM28, and VEGFA. The therapeutic potential of lisaftoclax was evaluated in combination with sunitinib. Proteomic profiling identified DHODH as a key regulator in the development of sunitinib resistance in RCC. Mechanistically, DHODH competes with the E3 ligase TRIM37 for binding to TRIM28, thereby stabilizing TRIM28 by inhibiting its ubiquitination. TRIM28 subsequently activates VEGFA transcription, which promotes sunitinib resistance in RCC. Lisaftoclax, a small‐molecule inhibitor that disrupts the DHODH‐TRIM28 interaction, potentiates sunitinib efficacy and exerts a synergistic therapeutic effect. Collectively, our findings identify DHODH as a critical therapeutic target for overcoming sunitinib resistance in RCC and provide a novel strategy for the treatment of RCC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
ORCID profiles: Shijie Qian, Shihang Pu, Zengjun Wang, Jiajun Xing, Aiming Xu
Funding
- Jiangsu Provincial Medical Key Discipline (Laboratory)
- Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- China Postdoctoral Science Foundation
Cite
APA
Qian, S., Pu, S., Xu, Z., Ding, Y., Jin, L., Li, B., Li, Q., Xi, X., Wang, Z., Xing, J., & Xu, A. (2026). DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC. Advanced Science. https://doi.org/10.1002/advs.76266
Vancouver
Qian S, Pu S, Xu Z, Ding Y, Jin L, Li B, et al. DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC. Advanced Science. 2026. doi:10.1002/advs.76266
BibTeX
@article{Qian2026,
author = {Qian, Shijie and Pu, Shihang and Xu, Zhipeng and Ding, Yiheng and Jin, Ling and Li, Baochao and Li, Qi and Xi, Xiaohai and Wang, Zengjun and Xing, Jiajun and Xu, Aiming},
title = {DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76266}
}
EUVIMED